We have a robust pipeline of wholly owned and partnered programmes to address a broad spectrum of disease indications.
Our foundation is built on our proprietary soluble TCR bi-specific ImmTAC® platform.
23 November 2020Immunocore’s tebentafusp demonstrates superior overall survival compared to investigator’s choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma
15 October 2020Immunocore Appoints Nobel Laureate Professor Sir Peter J. Ratcliffe as Non-Executive Director
27 August 2020Immunocore announces publication of preclinical data in Hepatology showing the potential of ImmTAV® bispecific molecules for functional cure of chronic hepatitis B